Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.

Saved in:
Bibliographic Details
Title: Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Authors: Tran G; Roche Products Pty Ltd, New South Wales, Australia. giao.tran@roche.com, Hack SP, Kerr A, Stokes L, Gibbs P, Price T, Todd C
Source: Asia-Pacific journal of clinical oncology [Asia Pac J Clin Oncol] 2013 Sep; Vol. 9 (3), pp. 239-48. Date of Electronic Publication: 2012 Dec 21.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Blackwell Pub. Asia Country of Publication: Australia NLM ID: 101241430 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-7563 (Electronic) Linking ISSN: 17437555 NLM ISO Abbreviation: Asia Pac J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1743-7563
DOI:10.1111/ajco.12044